Quantcast

Latest Diabetic foot Stories

2009-06-18 06:00:00

ASHBURN, Va., June 18 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced positive provisional findings from its three phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN TOPICAL for the treatment and prevention of infection in diabetic foot ulcers. Chronic ulcerations such as diabetic foot ulcers are often colonized or contaminated with bacterial pathogens that can prevent ulcers...

2009-05-26 09:28:03

Diabetes rates have risen sharply in developed countries in the wake of the obesity epidemic, and an estimated 30 million Europeans live with the condition. Foot problems are the most common cause of admission to hospital for diabetics, who are at risk of serious complications such as nerve damage and problems with the blood supply to their feet. Both conditions can lead to slow-healing wounds and foot ulcers which, if they get infected and become gangrenous, can lead to amputation. According...

2009-05-12 16:24:00

FARMINGDALE, N.Y., May 12 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has announced their attendance and participation in the annual Diabetic Foot Global Conference (DFCON), which was held in Los Angeles, CA, March 19-21, 2009. In addition to exhibiting its SonicOne(R) Ultrasonic Wound Cleansing and Debridement...

2009-05-12 08:15:00

SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that the Company will hold a conference call and webcast to discuss recent developments and future plans for its Excellarate(TM) clinical development program. (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO) On May 6, 2009, the Company announced the completion of recruitment for the Tissue Repair Company's pioneering gene therapy Phase 2b MATRIX clinical trial to evaluate the...

2009-05-07 08:00:00

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) today announced significant new formulation enhancements for its Excellarate(TM) product candidate that are designed to simplify and broaden the use of Excellarate for diabetic ulcers, and also expand the potential applicability into a number of additional wound healing market opportunities, including pressure and venous stasis ulcers, as well as major surgical and...

2009-05-06 16:37:00

SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) today announced the completion of recruitment for the pioneering Phase 2b MATRIX clinical trial to evaluate the safety and efficacy of the Excellarate(TM) product candidate for the potential treatment of non-healing foot ulcers in patients with type I or type II diabetes. Excellarate is designed to require only one or two physician-administered treatments, in...

2009-05-05 07:00:00

ADDISON, Texas, May 5 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE AMEX: ULU) announced today that clinical evidence utilizing Altrazeal(TM) Nanoflex Transforming Powder Dressing has been published in the respected peer-reviewed publication, International Wound Journal. The article, which is the first peer-review publication detailing clinical experience using Altrazeal(TM), was authored by a team of clinicians and scientists working at Southern Arizona Limb Salvage Alliance ("SALSA") at the...

2009-04-20 13:59:39

Treatment of chronic wounds is a continuing clinical problem and socio-economic burden with diabetic foot ulcers alone costing the NHS £300 million a year. Scientists in Bristol have found that human fetal stem cells can effectively be used to treat back leg ischaemic ulcers in a model of type 1 diabetes. The researchers also found the culture in which the stem cells had been grown mimicked the wound-healing ability of the cells, suggesting that they could be used as a "factory" of...

2009-04-06 08:00:00

TUCSON, Ariz., and GILROY, Calif., April 6 /PRNewswire/ -- The Department of Surgery at The University of Arizona College of Medicine and OmegaGenesis, Inc., announced an agreement to collaborate on potential remedies to address diabetic foot ulcers. The agreement includes joint work in support of potential remedies and to identify effective ways to provide information and education to medical professionals and patients globally. Diabetic foot ulcers are painful, open sores that develop...

2009-03-20 08:30:00

-- Accepted Abstract on CellerateRx Conducted by Dr. Matt Regulski -- FORT WORTH, Texas, March 20 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today that it is exhibiting at DFCon 09 on March 19-21, 2009 at the Renaissance Hollywood Hotel in Los Angeles, California. DFCon is considered the premier international multidisciplinary diabetic foot conference that attracts attendees from more than...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related